Genomics and the second golden era of cancer drug development

The Hallmarks of Cancer

2000 • 27,569 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Cancer: Principles and Practice of Oncology.

1991 • 8,402 citations

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

2002 • 5,914 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Can the pharmaceutical industry reduce attrition rates?

2004 • 3,946 citations

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2004 • 3,873 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

Proliferation, cell cycle and apoptosis in cancer

2001 • 3,236 citations

A census of human cancer genes

2004 • 3,190 citations

The druggable genome

2002 • 3,099 citations

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

2004 • 2,674 citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 • 2,285 citations

Protein kinases — the major drug targets of the twenty-first century?

2002 • 2,101 citations

Chemotherapy and the war on cancer

2005 • 1,927 citations

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

2004 • 1,785 citations

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

2000 • 1,770 citations

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

2004 • 1,600 citations

Synthesis and Function of 3-Phosphorylated Inositol Lipids

2001 • 1,527 citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 • 1,510 citations

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

2002 • 1,349 citations

PIK3CA is implicated as an oncogene in ovarian cancer

1999 • 1,170 citations

Navigating chemical space for biology and medicine

2004 • 977 citations

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1999 • 970 citations

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

2005 • 813 citations

Guilty as charged

2004 • 783 citations

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

2003 • 783 citations

Clinical biomarkers in drug discovery and development

2003 • 761 citations

Intragenic ERBB2 kinase mutations in tumours

2004 • 753 citations

The PIK3CA gene is mutated with high frequency in human breast cancers

2004 • 654 citations

The genetics and genomics of cancer

2003 • 570 citations

“Rapid-Impact Interventions”: How a Policy of Integrated Control for Africa's Neglected Tropical Diseases Could Benefit the Poor

2005 • 545 citations

Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers

2004 • 517 citations

Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers

2003 • 487 citations

NIH Molecular Libraries Initiative

2004 • 343 citations

BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90

2002 • 289 citations

PTEN, a unique tumor suppressor gene.

2000 • 266 citations

Micronutrient Sprinkles to Control Childhood Anaemia

2005 • 228 citations

Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice

2004 • 220 citations

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?

1999 • 206 citations

Altered states: selectively drugging the Hsp90 cancer chaperone

2004 • 205 citations

PI3-kinase inhibition: a target for drug development?

2000 • 194 citations

The Cyclin-dependent Kinase Inhibitor CYC202 ( R -Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway

2004 • 190 citations

Proteasome inhibition: a novel approach to cancer therapy

2002 • 183 citations

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

2003 • 171 citations

Why we're losing the war on cancer (and how to win it).

2004 • 161 citations

Somatic alterations in the human cancer genome

2004 • 159 citations

How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development

2003 • 150 citations

Overview: Translating Hsp90 Biology into Hsp90 Drugs

2003 • 139 citations

Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors

2003 • 126 citations

Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment

2004 • 85 citations

Histone modification enzymes: novel targets for cancer drugs

2004 • 78 citations

Histone modification enzymes: novel targets for cancer drugs

2004 • 77 citations

Challenges of PK/PD measurements in modern drug development

2002 • 67 citations

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones

2003 • 59 citations

Beyond Fast Track for Drug Approvals

2004 • 58 citations

Scoring a bull's-eye against cancer genome targets

2001 • 51 citations

A vision for the National Cancer Program in the United States

2004 • 49 citations

Inhibitors of HSP90 and other chaperones for the treatment of cancer

2004 • 45 citations

Drug discovery today. Therapeutic strategies

2013 • 43 citations

Therapeutic potential of phosphoinositide 3-kinase inhibitors

2004 • 35 citations

Signal transduction inhibitors—a work in progress

2004 • 35 citations

The combination of cytotoxic and molecularly targeted therapies – can it be done?

2004 • 17 citations

The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy

2004 • 16 citations

Mammalian primitive erythrocytes: neither fish nor fowl

2004 • 14 citations

γ-Secretase inhibitors: still in the running as Alzheimer’s therapeutics

2004 • 12 citations